India consults on compensating patients injured in drug, device trials
This article was originally published in Clinica
The Indian Council of Medical Research is inviting feedback from stakeholder on a draft guideline that explains how and when participants in pharmaceutical and medical device clinical trials should be compensated for any research-related injuries.
You may also be interested in...
A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule.
The UK regulator is expecting a rise in amendments and deviations to ongoing clinical investigations of medical devices due to the COVID-19 pandemic and has issued advice on how companies should manage these.
Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.